Cephalon Adds Warning On Life-Threatening Skin Reaction To Provigil
This article was originally published in The Pink Sheet Daily
FDA requests updated labeling recommending the wakefulness drug be discontinued if a rash or hypersensitivity reaction occurs.
You may also be interested in...
Company tells “The Pink Sheet” DAILY it is set to begin studies in other therapeutic areas to boost labeling before commercial launch.
Cephalon plans to submit information to FDA within “the next few weeks.”
Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.